

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al

Application No.: To be assigned

Group/Art Unit: To be assigned

Filed: February 5, 2002

Examiner: To be assigned

For: Compounds With Growth Hormone Releasing

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, after the title, insert

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of serial no.09/534,135 filed on March 23, 2000 which is divisional of U.S. application no. 09/218,686 filed December 21, 1998, which is a divisional of U.S. application no. 08/769,020 filed December 18, 1996 and claims priority under 35 U.S.C. 119 of Danish application nos. 1462/95, 0698/96, 0812/96 and 1248/96 filed December 22, 1995, June 25, 1996, July 24, 1996 and November 6, 1996, respectively, and of U.S. provisional application no. 60/022,062 filed July 22, 1996, the contents of which are fully incorporated herein by reference.

IN THE CLAIMS:

Please cancel claims 2-20.


REMARKS

Claims 2-20 have been canceled without prejudice or disclaimer. Therefore, claim 1 is pending in the present application.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Date: February 5, 2002

Respectfully submitted,


Cheryl H. Agis, Reg. No. 34,086
Outside Counsel for Novo Nordisk
of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE